Tetanus Toxoid Vaccine Market Research Report- Global Forecast till 2030

Tetanus toxoid vaccine market information: by types (monovalent Tetanus Toxoid (TT), Diphtheria, Tetanus, and Pertussis (DTaP), Diphtheria and Tetanus (DT), tetanus, diphtheria, and pertussis (Tdap), others) by forms (quadrivalent, pentavalent, hexavalent) by end users (hospitals and clinics, government organizations, research, others) - Global Forecast till 2030

ID: MRFR/Pharma/2707-HCR | 90 Pages | Author: Kinjoll Dey | March 2024         

Tetanus Toxoid Vaccine Market Speak to Analyst Request a Free Sample

Market Synopsis of global Tetanus toxoid vaccine market:

Market scenario:


The Tetanus toxoid vaccine market is projected to reach USD 7,236.2 Million by 2030 at 5.9% CAGR during the forecast period 2022-2030.Tetanus is an infectious disease caused by Clostridium tetani characterized by muscle spasms. The spasms may be very severe and even cause bone fractures. Other symptoms include fever, sweating, headache, trouble swallowing, hypertension etc. About 10% of those infected, die while a large number become incapacitated due to bone fractures. Tetanus toxoid vaccine is an inactive vaccine used to prevent tetanus by developing immunity against the pathogen causing tetanus. The general dosage recommendation is five doses during childhood, with a sixth given during adolescence with additional doses every 10 years. The tetanus vaccine was initially developed in 1924 and has resulted in a 95% decrease in the rate of tetanus in the US and is on the World Health Organization's List of Essential Medicines. The vaccine also is considered very safe even during pregnancy and for those with HIV.


The market restraints of the tetanus toxoid vaccine are redness and pain at the site of injection, fever, and fatigue and muscles pains. Severe allergic reactions are the most serious side effects of the Tetanus toxoid vaccine which occur in less than one in 100,000 people. The market for tetanus toxoid vaccine is bipolar with contractual market having a sizable number of share as compared to the private market. The other market constraints include falling profitability of vaccine manufacturing, huge reduction of tetanus in the developed world which effectively eliminates the need for further vaccination due to herd immunity, side effects associated with vaccines, variability of efficacy of tetanus toxoid vaccine etc.


The low profitability in vaccine manufacturing has reduced incentives for developing vaccines for diseases of the developing world such as tuberculosis and malaria.


 Tetanus Toxoid Vaccine Market Share


Sources: Mayo Clinic, MRFR Analysis.


Intended Audience



  • Global Tetanus toxoid vaccine manufacturers & suppliers

  • Research and development (R&D) companies

  • Hospitals and clinics

  • Academic institutes and universities


Figure 1 Global Tetanus toxoid vaccine market by End Users, 2016 (% Market Share)

Tetanus Toxoid Vaccine Market Outlook 


Segments:


The global tetanus toxoid vaccine market is segmented on the basis of types, forms and end users. Based on types, the market has been segmented as monovalent tetanus toxoid (TT), diphtheria, tetanus, and pertussis (DTaP), diphtheria and tetanus (DT), tetanus, diphtheria, and pertussis (Tdap) and others. Based on the forms, the market has been segmented as quadrivalent, pentavalent, and hexavalent. Based on the end users, the market has been segmented as biotech and hospitals and clinics, government organizations, research and others.


Regional analysis


US accounts for the maximum market share due to greater use of medications and greater expenditure on healthcare. The faster market uptake of new technology and devices in the US is also an important driver of the market for global Tetanus toxoid vaccine. Europe is the second largest market due to large disposable income and rising awareness. Asia Pacific region is expected to have the most future potential and it is estimated to be led by China and India. The Middle East & Africa market is led by the gulf nations particularly Saudi Arabia and UAE. The regions of Africa are expected to witness a moderate growth due to poor economic and political conditions and poor healthcare penetration.


Key players of Global Tetanus toxoid vaccine market:


Key players profiled in the report are GlaxoSmithKline Plc., Merck & Co. Inc., Pfizer, Inc., Sanofi Pasteur, Inc., AstraZeneca Plc., Bharat Biotech, Shenzhen Kangtai Biological Products, Valeant Pharmaceuticals, Emergent Biosolutions Inc., Astellas Pharma Inc., Panacea Biotec and others. The report for Global Tetanus toxoid vaccine market by Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain a deeper insight of the market and industry performance. The report gives a clear picture of the current market scenario which includes past and estimated future market size with respect to value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information about and strategies used by top key players in the industry. The report also gives a broad study of the different market segments and regions.

Report Scope:

Report Attribute/Metric Details
  Market Size   USD 7,236.2 Million
  CAGR   5.9%
  Base Year   2021
  Forecast Period   2022-2030
  Historical Data   2020
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Types, Forms, End Users
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   GlaxoSmithKline Plc., Merck & Co. Inc., Pfizer, Inc., Sanofi Pasteur, Inc., AstraZeneca Plc., Bharat Biotech, Shenzhen Kangtai Biological Products, Valeant Pharmaceuticals, Emergent Biosolutions Inc., Astellas Pharma Inc., Panacea Biotec
  Key Market Opportunities ·  US accounts for the maximum market share due to greater use of medications and greater expenditure on healthcare ·  Europe is the second largest market due to large disposable income and rising awareness
  Key Market Drivers ·  Profitability of vaccine manufacturing ·  Huge reduction of tetanus in the developed world which effectively eliminates the need for further vaccination due to herd immunity
 



Frequently Asked Questions (FAQ) :

Tetanus toxoid vaccine market CAGR would be 5.9% during the forecast period.

Tetanus toxoid vaccine market valuation would be USD 7,236.2 Million by 2030.

The US would dominate the North American tetanus toxoid vaccine market.

The end users mentioned in the tetanus toxoid vaccine market report are government organizations, research, biotech and hospitals and clinics, and others.

The types discussed in the tetanus toxoid vaccine market report are tetanus, and pertussis (DTaP), monovalent tetanus toxoid (TT), diphtheria, tetanus, diphtheria, and pertussis (Tdap), diphtheria and tetanus (DT), and others.

Key Questions Answered

  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Request Free Sample

Why Choose Market Research Future?

  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.
Speak to Analyst
Leading companies partner with us for data-driven Insights.
Client logo Client logo Client logo Client logo Client logo Client logo Client logo Client logo Client logo Client logo

Kindly complete the form below to receive a free sample of this Report

Please fill in Business Email for Quick Response
Invalid